Your session is about to expire
← Back to Search
Other
PGB/LFX; for Opioid Withdrawal Syndrome (PGB-LOF Trial)
Phase 2
Waitlist Available
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Summary
This trial will investigate whether pregabalin combined with lofexidine can reduce opioid withdrawal-related subjective effects and increase the proportion of patients with an opioid use disorder who complete detoxification and transition to antagonist treatment with extended-release injectable naltrexone.
Eligible Conditions
- Opioid Withdrawal Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 7 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Subjective Opioid Withdrawal Scale-Gossop (SOWS) Scale Score
Secondary study objectives
Completion of Withdrawal Management
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: PGB/LFX;Experimental Treatment2 Interventions
0.54 mg lofexidine and 200 mg Pregabalin on days 1 -7 with taper for pregabalin and lofexidine starting on day 5
Group II: Lofexidine and PLACEBOActive Control2 Interventions
0.54 mg lofexidine and Placebo (PLB) on days 1-7 with taper for lofexidine starting on day 5
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lofexidine 0.18Mg Tab
2020
Completed Phase 2
~90
Pregabalin 200 MG capsules
2020
Completed Phase 2
~90
Find a Location
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
2,076 Previous Clinical Trials
42,719,735 Total Patients Enrolled
Stuart WatsonStudy DirectorOffice of Research Administration, Univ. of Pennsylvania
Share this study with friends
Copy Link
Messenger